IPO Timeline
Broker Results (T-2)
2023-07-07
Some brokers release in afternoon
Grey Market (T-1)
2023-07-10
Afternoon
HKEX Allotment (T-1)
2023-07-10
Evening
Registrar Allotment (T-1)
2023-07-10
Evening
Listing Day (T)
2023-07-11
First day of trading
Company Overview
| Stock Name | 科伦博泰生物－Ｂ |
|---|---|
| Stock Code | 06990 |
| Company Full Name | 科伦博泰生物－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家創新的生物醫藥公司，致力于創新藥物的研發、制造及商業化，以解決中國乃至全球的醫療需求。 |
| Listing Date | 2023-07-11 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國四川省成都市溫江區成都海峽兩岸科技產業開發園新華大道666號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://kelun-biotech.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 60.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 38.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 136,028,820 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 6,060 |
| 2 lots | 200 | HK$ 12,120 |
| 3 lots | 300 | HK$ 18,180 |
| 4 lots | 400 | HK$ 24,240 |
| 5 lots | 500 | HK$ 30,300 |
| 6 lots | 600 | HK$ 36,360 |
| 7 lots | 700 | HK$ 42,420 |
| 8 lots | 800 | HK$ 48,480 |
| 9 lots | 900 | HK$ 54,540 |
| 10 lots | 1,000 | HK$ 60,600 |
| 15 lots | 1,500 | HK$ 90,900 |
| 20 lots | 2,000 | HK$ 121,200 |
| 25 lots | 2,500 | HK$ 151,500 |
| 30 lots | 3,000 | HK$ 181,800 |
| 35 lots | 3,500 | HK$ 212,100 |
| 40 lots | 4,000 | HK$ 242,400 |
| 45 lots | 4,500 | HK$ 272,700 |
| 50 lots | 5,000 | HK$ 303,000 |
| 60 lots | 6,000 | HK$ 363,600 |
| 70 lots | 7,000 | HK$ 424,200 |
| 80 lots | 8,000 | HK$ 484,800 |
| 100 lots | 10,000 | HK$ 606,000 |
| 150 lots | 15,000 | HK$ 909,000 |
| 200 lots | 20,000 | HK$ 1,212,000 |
| 250 lots | 25,000 | HK$ 1,515,000 |
| 300 lots | 30,000 | HK$ 1,818,000 |
| 350 lots | 35,000 | HK$ 2,121,000 |
| 400 lots | 40,000 | HK$ 2,424,000 |
| 450 lots | 45,000 | HK$ 2,727,000 |
| 500 lots | 50,000 | HK$ 3,030,000 |
| 600 lots | 60,000 | HK$ 3,636,000 |
| 700 lots | 70,000 | HK$ 4,242,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 100,000 | HK$ 6,060,000 |
| 2,000 lots | 200,000 | HK$ 12,120,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 62.5 |
|---|---|
| First Day Open | HK$ 60.6 |
| First Day Change | 3.14% |
| First Day Volume | 2002300.0 |
| First Day Turnover | 124404000.0 |
Use of Proceeds
| Use of Proceeds | 1、約45.0%或566.5百萬港元將用于研發并商業化核心產品SKB264及A166； 2、約30.0%或377.7百萬港元將用于其他主要產品的研發及商業化； 3、約12.0%或151.1百萬港元將用于為持續開發技術平臺、推進其他現有管線資產以及探索并開發新候選藥物提供資金； 4、約8.0%或100.7百萬港元將用于擴充產能及質量控制系統，以支持后期資產的預期商業化； 5、約5.0%或62.9百萬港元將用于營運資金及其他一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
高盛（亚洲）有限责任公司 CE ACC536
中信证券（香港）有限公司 CE AAK249
Overall Coordinators (3)
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
花旗环球金融亚洲有限公司 CE AAA137
Joint Bookrunners (5)
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
花旗环球金融亚洲有限公司 CE AAA137
工银国际证券有限公司 CE ARO299
交银国际证券有限公司 CE APJ121
Joint Lead Managers (5)
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
花旗环球金融亚洲有限公司 CE AAA137
工银国际证券有限公司 CE ARO299
交银国际证券有限公司 CE APJ121
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Laurion Capital Master Fund, Ltd. | 56,939,760 HKD | — | 4.20% | — | 6 months | 2024-01-11 |
| 2 | RTW Funds | 117,224,640 HKD | — | 8.60% | — | 6 months | 2024-01-11 |
| 3 | TruMed | 56,939,760 HKD | — | 4.20% | — | 6 months | 2024-01-11 |
| 4 | 汇添富基金管理股份有限公司 | 65,490,420 HKD | — | 4.80% | — | 6 months | 2024-01-11 |
| 5 | 科伦国际发展有限公司 | 229,231,620 HKD | — | 16.90% | — | 6 months | 2024-01-11 |
Directors & Management
| Chairman | 劉革新 |
|---|---|
| Company Secretary | 周澤劍;鐘明輝 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 四川科倫藥業股份有限公司(55.13%);雇員激勵平臺(13.90%);默沙東(6.23%);Wealthy Linkage(3.37%);先進制造產業投資基金(3.31%) |
|---|
Subscription Tiers
IPO Timeline
